Sign In
Buy TLSA
$1.18
-0.180 (-13.24%)
At Close: Jun 03, 2026
Tiziana Life Sciences reports brain inflammation reductions in Multiple System Atrophy trial
09:08am, Thursday, 14'th May 2026
Tiziana Life Sciences Ltd (NASDAQ:TLSA) reported PET imaging results from two patients in a Phase 2 Multiple System Atrophy trial showing up to 35% and 24% reductions in brain inflammation markers fol
Tiziana Reports Reduced Brain Inflammation in Multiple System Atrophy Patients Treated with Intranasal Foralumab
07:00am, Thursday, 14'th May 2026
BOSTON, May 14, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD
S&P and Nasdaq close at record highs on ceasefire optimism and tech strength
12:22pm, Thursday, 16'th Apr 2026
4:20pm: Tech powers gains Stocks finished higher on Thursday, with both the S&P 500 and Nasdaq notching fresh record closes as investors continued to lean...
Tiziana says intranasal drug shows potential to ease Long COVID “brain fog”
09:00am, Thursday, 16'th Apr 2026
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Thursday that preclinical research on its experimental intranasal therapy showed potential to reduce brain inflammation and improve cognitive function l
Data from independent academic collaborators published on bioRxiv support the therapeutic potential of the Company's lead candidate, intranasal foralumab, for Long COVID associated “brain fog”. Da
Abbott Labs shares fall as earnings beat offset by Exact Sciences acquisition drag
06:48am, Thursday, 16'th Apr 2026
Shares of Abbott Laboratories (NYSE:ABT) fell 3.2% on Thursday morning after the healthcare conglomerate marginally beat Wall Street estimates for quarterly...
Tiziana says intranasal drug shows potential to ease Long COVID “brain fog”
04:58am, Thursday, 16'th Apr 2026
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Thursday that preclinical research on its experimental intranasal therapy showed potential to reduce brain...
Tiziana Life Sciences to present Phase 2a MSA study at World Parkinson Congress
09:03am, Tuesday, 14'th Apr 2026
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Tuesday a late-breaking poster on its Phase 2a study of intranasal foralumab in Multiple System Atrophy (MSA) has been accepted for presentation at the
Tiziana Life Sciences Announces Late Breaking Poster Accepted for Presentation at the 7th World Parkinson Congress
07:00am, Tuesday, 14'th Apr 2026
BOSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-
Ollie’s Bargain Outlet upgrade driven by outlet expansion, margin stability
08:02am, Thursday, 02'nd Apr 2026
Ollie's Bargain Outlet (NASDAQ:OLLI) has been upgraded to a ‘Buy’ rating by Jefferies analysts, who cited the company’s strong market position,...
Hochschild and Fresnillo slip as gold price knocked by Trump speech on Iran
05:10am, Thursday, 02'nd Apr 2026
Hochschild Mining PLC (LSE:HOC, OTCQX:HCHDF) and Fresnillo PLC (LSE:FRES) led a broad sell-off in FTSE 350 precious metals stocks on Thursday morning as...
Tiziana Life Sciences Stock Jumps As Positive Preclinical Fuels Momentum
01:10pm, Wednesday, 01'st Apr 2026
The recent data highlight nasal anti-CD3's potential in reversing cognitive decline associated with aging, which is a significant concern in neurodegenerative diseases.
Tiziana Life Sciences reports positive preclinical findings for intranasal anti-CD3 therapy in brain aging
09:20am, Wednesday, 01'st Apr 2026
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has unveiled new preclinical data suggesting that its investigational therapy, intranasal foralumab, may offer a novel approach to addressing neuroinflammation
RH stock tanks as fourth quarter results miss on the top and bottom lines
07:25am, Wednesday, 01'st Apr 2026
RH (NYSE:RH), the high-end home furnishings retailer, reported weaker-than-expected results for the fourth quarter of fiscal 2025, sending its shares down...
Tiziana Announces Data Showing Nasal Anti-CD3 Improves Cognition Associated with Aging
07:00am, Wednesday, 01'st Apr 2026
BOSTON, April 01, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti
